We are pleased to share the latest CIRS newsletter with you, providing an update on our recent activities, research outputs, and upcoming work across medicine regulation and HTA.
🔍In this issue:
- Strategic Summit: Global stakeholders shared perspectives to help shape CIRS’ 2027–2029 research agenda.
- R&D Briefing 104: Analysis of Class 1 innovative medicines approved in China, including regulatory pathways and reimbursement outcomes.
- Global engagement: Highlights from recent conferences and meetings contributing to discussions on regulatory and HTA developments worldwide.
- Upcoming webinar: A session on advancing regulatory reliance, bringing together international perspectives and experiences.
- Forthcoming research: Previews of upcoming briefings on regulatory agency benchmarking and the evolving EU HTA landscape.
